Mizuho lowered the firm’s price target on Edwards Lifesciences (EW) to $95 from $100 and keeps an Outperform rating on the shares. The firm lowered estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $92 from $94 at Evercore ISI
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Outperform from Peer Perform at Wolfe Research
- Edwards Lifesciences: TRISCEND II Data and EVOQUE Differentiation Underpin Buy Rating and Long-Term Growth Outlook
- Edwards Lifesciences announces new data on EVOQUE TTVR system